ArticleFrontiers in immunology2025
Cross-tissue transcriptome-wide association identify novel T1D susceptibility genes and drug candidates.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The genetic mechanisms underlying type 1 diabetes (T1D) remain incompletely understood, limiting the development of targeted therapies. Methods: We performed an integrative genetic analysis to identify T1D susceptibility genes and therapeutic targets. This included a cross-tissue transcriptome-wide association study (TWAS) to pinpoint genes with genetically predicted expression associated with T1D risk, followed by Mendelian randomization to infer causality. Identified genes were further characterized through pathway, cell-type enrichment, drug prediction, molecular docking, and phenome-wide association studies. Results: We identified ten genes associated with T1D risk, seven of which (ELK4, PHACTR4, MAST2, ST7L, C1orf216, SULT1A2, and WFS1) are novel candidates in this context. Three genes (ELK4, SULT1A2, and WFS1) were prioritized as druggable targets, with COMPOUND 5G and DCLK1-IN-1 emerging as potential therapeutic agents through computational analyses. Conclusion: Our study reveals novel genetic associations and immune-related pathways in T1D pathogenesis, and proposes specific genes and compounds as promising focal points for future mechanistic and therapeutic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.